Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel

The role of natural killer (NK) cells in retrovirus induced leukaemogenesis was studied. Neonate BALB/c mice infected the Moloney murine leukaemia virus (MoLV) develop leukaemia. The MoLV infected mice showed a progressive loss of endogenous or augmented NK activity, correlated with the development of the leukaemic state. Mixing of spleen cells from tumour bearing mice with NK augmented splenocytes, resulted in suppression of NK activity. In addition, mixing of T cell lines isolated from MoLV induced tumours with augmented splenocytes also resulted in the down regulation of NK cell activity. It is postulated that after MoLV infection, the progression of virus transformed T cells to a fully developed tumour depends on the ability of these cells to down regulate NK cell activity and thus evade immune surveillance.

REGULATION OF MAMMALIAN DNA REPAIR ENZYMES DURING THE CELL CYCLE

Lisbeth C.Olsen(1), Dag E.Helland(1) and Ian Pryme(2)

(1)Laboratory of Biotechnology and (2)Department of Biochemistry, Univerity of Bergen, Norway

We have studied the regulation of mammalian DNA repair enzymes as a function of the cell cycle. Synchronous populations of L-929 cells in early G1 were obtained using centrifugal elutriation. Synchronous populations of early G1 cells were reestablished in culture and harvested at different intervals during the cell cycle. Enzyme extracts were prepared by a high salt wash of purified nuclei. The results indicate that DNA repair enzymes redoxy-endonuclease, ^{3}Me-adenine-DNA-glycosylase, uracil-DNA-glycosylase and Ap-endonuclease all have an increased activity in late G1 prior to the onset of DNA synthesis. The O^{6}-Me-guanine transferase activity, however, was present at the same level in all stages of the cell cycle studied. We conclude from these experiments that the majority of mammalian DNA repair enzymes are cell cycle dependently expressed.

BIOLOGICAL AND MOLECULAR PROPERTIES OF p53

Moshe Oren, Dan Michalovitz, Orit Pinhasi-Kimhi and Danny Eliyahu

Department of Chemical Immunology, The Weizmann Institute of Science, Rehovot, Israel

p53 is a cellular protein found in elevated levels in a variety of tumour-derived and *in vitro* transformed cells. To investigate the possible role of p53 in transformation, we cloned p53-specific DNA and used it to construct p53 expression plasmids. The introduction of such plasmids into non-transformed cells, either alone or together with Ha-*ras*, led to neoplastic conversion, thus implicating p53 as an oncogenic protein possessing *myc*-like activities. This notion was also confirmed by experiments indicating that p53 can serve as a competence factor in the control of normal cellular proliferation. Finally, p53 was shown to form a tight complex with a major heat-shock protein, raising the possibility that stress proteins may also play a role in proliferation-related processes.

CORRELATION BETWEEN HLA-A,B,C EXPRESSION ON HUMAN UROTHELIAL CELL LINES AND TRANSFORMATION GRADE *IN VITRO*

S.S.Ottesen, B.Christensen and J.Kieler

The Fibiger Institute, Copenhagen, Denmark

Various characteristics of human urothelial cell lines permit a classification of these cell lines according to grade of transformation (TGr) *in vitro*. Of special interest here is that the slightly transformed (TGrI) and pre-tumourigenic (TGrII) cell lines all express the appropriate HLA-A,B epitopes in contrast to the tumourigenic (TGrIII) cell lines. Using the immunofluorescence test and a complement dependent cytotoxicity test we have investigated 3 TGrII and 7 TGrIII cell lines for their expression of the monomorphic part of HLA-A,B,C antigens. We provide evidence that the apparent loss of HLA-A,B epitopes observed in TGrIII cells is due to a significantly (4 to 6 fold) lower concentration of HLA-A,B,C antigens on TGrIII cells as compared to that on TGrII cells. Furthermore, treatment of TGrIII cells with neuraminidase partly restored the expression of HLA-A,B,C antigens.

THE EFFECT OF CELLADAM ON EHRLICH AND S180 TUMOURS

K.Pal, A.Vertesy, E.Szigeti, P.Szego and A.Kovacs

Celladam Cancer Research Group, Pilisborosjeno, Hungary

A new anticancer and immunostimulant